Quantcast
Last updated on April 18, 2014 at 10:13 EDT

Latest Psoriatic arthritis Stories

2009-05-28 07:41:00

EXTON, Pa., May 28 /PRNewswire/ -- BioTrends Research Group today released its syndicated report TreatmentTrends(R): Psoriasis, the fourth annual survey of U.S. Dermatologists (n=150). The report, based on results of an on-line survey fielded in April, highlights shifting trends in the management of psoriasis and psoriatic arthritis. This comprehensive report covers treatment approaches for mild, moderate, and severe patients with an emphasis on the evolving use of biologic agents. The...

2009-04-27 20:00:00

EXTON, Pa., April 27 /PRNewswire/ -- BioTrends is pleased to announce the fielding of a new syndicated report, LaunchTrends(TM): SIMPONI(R). Cenotcor Ortho Biotech, Inc. announced that they received FDA approval for SIMPONI(R) (generic name: golimumab) on April 24, 2009. The first once-monthly subcutaneous anti-TNF-alpha therapy, SIMPONI is approved for the treatment of moderately to severely active rheumatoid arthritis, active psoriatic arthritis, and active ankylosing spondylitis. The...

2009-04-27 08:31:40

The U.S. Food and Drug Administration says it has approved Simponi, a monthly injectable treatment for three types of arthritis. The FDA said Simponi (golimumab) was approved for use by adults with moderate-to-severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis. All three conditions are chronic disorders in which the immune system attacks multiple joints, causing stiffness, pain and restricted motion. Today's approval provides another treatment option for...

2009-04-14 05:00:00

- The second approved antibody generated from Medarex's UltiMAb(R) technology platform - PRINCETON, N.J., April 14 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced that it will receive a milestone payment of an undisclosed amount from its licensing partner, Centocor Ortho Biotech Inc., in connection with the marketing approval from Health Canada's Biologics and Genetic Therapies Directorate, to market SIMPONI(TM) (golimumab, also known as CNTO 148) as a once-monthly...

2009-04-13 15:15:00

Canadian Approval Is World's First Regulatory Approval for SIMPONI HORSHAM, Pa. and KENILWORTH, N.J., April 13 /PRNewswire-FirstCall/ Centocor Ortho Biotech Inc. and Schering-Plough Corporation (NYSE: SGP) today announced that Health Canada has granted approval of SIMPONI (TM) (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderately to severely active rheumatoid arthritis (RA), active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS)....

2009-03-11 14:35:00

Grammy Award-winning singer advocates for research into disease afflicting 7.5 million Americans WASHINGTON, March 11 /PRNewswire-USNewswire/ -- Grammy Award-winning artist LeAnn Rimes shared her personal story on Capitol Hill today about growing up with psoriasis, and she encouraged lawmakers to support much-needed research and enact legislation to address this complex, autoimmune disease. "I was first diagnosed with psoriasis at age 2 and throughout my childhood, my condition worsened to...

2009-03-11 05:00:00

Medicated Arthri-Zen Relief Cream(R) Clinically Shown to Work for up to 8 Hours MIAMI, March 11 /PRNewswire/ -- Every day, 70 million Americans suffer from the aches and pains that come with arthritis and other chronic joint problems(1). One of the most effective ways to get fast relief from arthritis pain is the use of analgesic creams. The only problem is that the relief tends to be short-lived. Many people find that within 45 minutes to an hour and a half after applying a cream, the pain...

2009-03-04 07:10:00

Campaign Sponsored by Amgen and Wyeth Offers a Chance to Win a Walk on the Runway in New York City Fashion Show NEW YORK, March 4 /PRNewswire-FirstCall/ -- Amgen and Wyeth today announced that they have partnered with Tim Gunn, television host and fashion consultant ("Project Runway," "Tim Gunn's Guide to Style") to launch Addressing Psoriasis(TM), an awareness campaign designed to help people with plaque psoriasis get more information about managing their disease and feel more confident in...

2009-03-02 09:21:00

Dermatologists cite high efficacy-to-safety ratio of topical agents for patients with mild to moderate psoriasis SCHAUMBURG, Ill., March 2 /PRNewswire-USNewswire/ -- The American Academy of Dermatology (Academy) has released new guidelines of care for the management and treatment of psoriasis with topical therapies based on an extensive review of scientific literature on the subject and recommendations of recognized psoriasis experts. This is the Academy's third of six sections of the...

2009-01-26 08:50:41

Scientists at the University of Michigan Department of Dermatology, the U-M School of Public Health and their collaborators have found DNA "hotspots" that may reveal how genetic differences among individuals result in psoriasis, an autoimmune disease of the skin. Published in Nature Genetics, the findings could lead to new drug targets and tailored treatments for the disease. "This discovery highlights the role of several genes in mediating the immune responses that result in psoriasis," says...